CIK 0001851194
VTYX Ventyx Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Mar 4, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Ventyx Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Raju Mohan CEO AND PRESIDENT sell | $365k 47,345 shares | -2% | - | |
| 18Weak | John Nuss CHIEF SCIENTIFIC OFFICER sell | $98k 12,675 shares | -3% | - | |
| 15Weak | John Nuss CHIEF SCIENTIFIC OFFICER sell | $2,019 1,887 shares | -0% | - | |
| 22Weak | John Nuss CHIEF SCIENTIFIC OFFICER sell | $50k 21,119 shares | -4% | - | |
| 37Weak | Sheila Gujrathi director buy | $301k 130,000 shares | - | - | |
| 5Weak | John Nuss CHIEF SCIENTIFIC OFFICER sell | $30k 13,161 shares | -3% | - | |
| 55Moderate | Raju Mohan CEO AND PRESIDENT buy | $960k 500,000 shares | +30% | - |
Transactions
The last 42 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | Onaiza Cadoret-Manier director | DDisposition to issuer Stock Option (Right to Buy)derivative | -33,000 | - | - | 0 | Mar 4, 2026 |
| Mar 4, 2026 | Onaiza Cadoret-Manier director | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,000 | - | - | 0 | Mar 4, 2026 |
| Mar 4, 2026 | Onaiza Cadoret-Manier director | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,000 | - | - | 0 | Mar 4, 2026 |
| Mar 4, 2026 | Onaiza Cadoret-Manier director | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,937 | - | - | 0 | Mar 4, 2026 |
| Mar 4, 2026 | Onaiza Cadoret-Manier director | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,427 | - | - | 0 | Mar 4, 2026 |
| Dec 17, 2025 | Raju Mohan CEO AND PRESIDENT | MOption exercise Common Stock | +116,668 | $0.00 | $0 | 2,420,208 | Dec 19, 2025 |
| Dec 17, 2025 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +34,930 | $0.00 | $0 | 502,156 | Dec 19, 2025 |
| Dec 18, 2025 | Raju Mohan CEO AND PRESIDENT | SOpen-market sale Common Stock | -47,345 | $7.72 | $365k | 2,372,863 | Dec 19, 2025 |
| Dec 18, 2025 | John Nuss CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -12,675 | $7.72 | $98k | 489,481 | Dec 19, 2025 |
| Dec 17, 2025 | Raju Mohan CEO AND PRESIDENT | MOption exercise Restricted Stock Unitsderivative | -116,668 | $0.00 | $0 | 0 | Dec 19, 2025 |
| Dec 17, 2025 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Restricted Stock Unitsderivative | -34,930 | $0.00 | $0 | 0 | Dec 19, 2025 |
| Nov 17, 2025 | Mark S Forman Chief Medical Officer | AGrant or award Common Stock | +3,000 | $1.03 | $3,090 | 6,000 | Nov 19, 2025 |
| Nov 17, 2025 | Roy Gonzales Senior VP, Finance | AGrant or award Common Stock | +1,767 | $1.03 | $1,820 | 5,313 | Nov 19, 2025 |
| Jun 5, 2025 | Onaiza Cadoret-Manier director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 6, 2025 |
| Jun 5, 2025 | Sheila Gujrathi director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 6, 2025 |
| Jun 5, 2025 | Allison Hulme director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 6, 2025 |
| Jun 5, 2025 | Somu Subramaniam director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 6, 2025 |
| Jun 5, 2025 | William Richard White director | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 6, 2025 |
| May 15, 2025 | Mark S Forman Chief Medical Officer | AGrant or award Common Stock | +3,000 | $1.03 | $3,090 | 3,000 | May 16, 2025 |
| May 15, 2025 | Roy Gonzales Senior VP, Finance | AGrant or award Common Stock | +1,750 | $1.03 | $1,803 | 3,546 | May 16, 2025 |
| Apr 2, 2025 | John Nuss CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -1,887 | $1.07 | $2,019 | 467,226 | Apr 3, 2025 |
| Mar 28, 2025 | Raju Mohan CEO AND PRESIDENT | MOption exercise Common Stock | +11,844 | $0.00 | $0 | 2,303,540 | Apr 1, 2025 |
| Mar 28, 2025 | Somu Subramaniam director | JOther Common Stockindirect: See Footnote | -1,335,450 | $0.00 | $0 | 4,032,213 | Apr 1, 2025 |
| Mar 28, 2025 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +4,531 | $0.00 | $0 | 469,113 | Apr 1, 2025 |
| Mar 28, 2025 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Restricted Stock Unitsderivative | -4,531 | $0.00 | $0 | 9,063 | Apr 1, 2025 |
| Mar 28, 2025 | Raju Mohan CEO AND PRESIDENT | MOption exercise Restricted Stock Unitsderivative | -11,844 | $0.00 | $0 | 23,688 | Apr 1, 2025 |
| Jan 2, 2025 | Mark S Forman Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +85,000 | $0.00 | $0 | 85,000 | Jan 3, 2025 |
| Jan 2, 2025 | Roy Gonzales Senior VP, Finance | AGrant or award Stock Option (Right to Buy)derivative | +109,200 | $0.00 | $0 | 109,200 | Jan 3, 2025 |
| Jan 2, 2025 | Roy Gonzales Senior VP, Finance | AGrant or award Stock Option (Right to Buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jan 3, 2025 |
| Dec 27, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -21,119 | $2.36 | $50k | 464,582 | Dec 30, 2024 |
| Dec 23, 2024 | Sheila Gujrathi director | POpen-market purchase Common Stockindirect: See Footnote | +130,000 | $2.31 | $301k | 130,000 | Dec 26, 2024 |
| Dec 17, 2024 | Raju Mohan CEO AND PRESIDENT | MOption exercise Common Stock | +116,668 | $0.00 | $0 | 2,291,696 | Dec 19, 2024 |
| Dec 17, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +34,930 | $0.00 | $0 | 498,862 | Dec 19, 2024 |
| Dec 17, 2024 | Raju Mohan CEO AND PRESIDENT | MOption exercise Restricted Stock Unitsderivative | -116,668 | $0.00 | $0 | 116,668 | Dec 19, 2024 |
| Dec 19, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -13,161 | $2.26 | $30k | 485,701 | Dec 19, 2024 |
| Dec 17, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Restricted Stock Unitsderivative | -34,930 | $0.00 | $0 | 34,930 | Dec 19, 2024 |
| Dec 10, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +5,377 | $0.20 | $1,075 | 270,375 | Dec 11, 2024 |
| Dec 10, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Common Stock | +193,557 | $0.20 | $39k | 463,932 | Dec 11, 2024 |
| Dec 10, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Stock Option (right to buy)derivative | -5,377 | $0.00 | $0 | 0 | Dec 11, 2024 |
| Dec 10, 2024 | John Nuss CHIEF SCIENTIFIC OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -193,557 | $0.00 | $0 | 0 | Dec 11, 2024 |
| Nov 22, 2024 | Raju Mohan CEO AND PRESIDENT | POpen-market purchase Common Stock | +238,248 | $1.83 | $435k | 1,913,276 | Nov 25, 2024 |
| Nov 25, 2024 | Raju Mohan CEO AND PRESIDENT | POpen-market purchase Common Stock | +261,752 | $2.01 | $525k | 2,175,028 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Onaiza Cadoret-Manierdirector
- Mark S FormanChief Medical Officer
- Roy GonzalesSenior VP, Finance
- Sheila Gujrathidirector
- Allison Hulmedirector
- Raju MohanCEO AND PRESIDENT
- John NussCHIEF SCIENTIFIC OFFICER
- Somu Subramaniamdirector
- William Richard Whitecfo, officer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.